BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2020 10:31:56 AM | Browse: 895 | Download: 1248
 |
Received |
|
2020-02-26 15:19 |
|
Peer-Review Started |
|
2020-02-26 15:20 |
|
First Decision by Editorial Office Director |
|
2020-03-27 18:56 |
|
Return for Revision |
|
2020-04-04 10:48 |
|
Revised |
|
2020-04-18 13:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-05-12 08:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-05-13 06:26 |
|
Articles in Press |
|
2020-05-13 06:26 |
|
Edit the Manuscript by Language Editor |
|
2020-05-29 01:43 |
|
Typeset the Manuscript |
|
2020-06-23 09:11 |
|
Publish the Manuscript Online |
|
2020-06-24 10:31 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Progress in immunotherapy for small cell lung cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dong Zhao, Bing Xie, Yong Yang, Peng Yan, Sheng-Nan Liang and Qiang Lin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com |
| Key Words |
Small-cell lung cancer; Programmed death-1 inhibitors; Cytotoxic T lymphocyte-associated antigen-4 inhibitors; Poly adenosine diphosphate ribose polymerase inhibitors; ; |
| Core Tip |
Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. Classical radiotherapy and chemotherapy have a plateauing effect. Immunotherapy is becoming an important treatment strategy for SCLC. In this article we review the recent advances in immunotherapy for SCLC. |
| Publish Date |
2020-06-24 10:31 |
| Citation |
Zhao D, Xie B, Yang Y, Yan P, Liang SN, Lin Q. Progress in immunotherapy for small cell lung cancer. World J Clin Oncol 2020; 11(6): 370-377 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i6/370.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i6.370 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
